Five tissue antigens have been identified which appear in carcinoma arising in the ovary. Antisera to a variety of human tissues were absorbed with a saline extract of normal ovary as well as plasma; five distinct antigens (A1-A4, TA) were detected in ovarian tumor extracts as well as in normal tissues. Al, A2, and A3 were widely distributed in normal tissues while A4 was found principally in buffy coat blood cells and spleen, and TA was mainly associated with normal cervix but was variably detected in liver and lung. Heating the tumor extract to 56° resulted in inactivation of Al, A2, and A3. A4 was inactivated at 80°, whereas TA was stable at 100°. Pronase treatment readily abolished A3 activity, more slowly inactivated Al, A2, and A4, and only very slowly destroyed TA. Partial separation of the antigens was obtained by Sephadex G-200 chromatography. TA from individual benign and malignant tumors as well as normal cervix appears to be the same molecule by criteria of immunodiffusion, Immunoelectrophoresis, and gel filtration. The potential use of these antigens as tracers of ovarian carcinoma is indicated.

Keywords:
Tissue antigens, Ovarian neoplasms
This content is only available via PDF.
© 1977 S. Karger AG, Basel
1977
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.